SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 17, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency’s review to be complete in April 2021.
{iframe}https://www.biospace.com/article/releases/united-therapeutics-announces-u-s-fda-filing-acceptance-of-supplemental-new-drug-application-for-tyvaso-for-pulmonary-hypertension-associated-with-interstitial-lung-disease/{/iframe}